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Abstract
Mutations of mediator subcomplex 12 (MED12) and of high mobility group protein AT-hook 2 (HMGA2) are driver
mutations in uterine leiomyomas (UL) that have not been observed to coexist in one tumor and even rarely coexist in
different UL tumors of one patient. Here we describe a patient who underwent hysterectomy because of multiple
leiomyomas which were studied by cytogenetics, MED12 hotspot sequencing, and copy number variation arrays. Two
of the UL tumors had different HMGA2 rearrangements not detected by G-banding. Two UL tumors had deletions of
the long arm of chromosome 3, in one case associated with a MED12 mutation. Both deletions lead to the loss of
MED12L showing strong similarity with MED12. It remains to be determined if this gene can play a role in
leiomyomagenesis independent of MED12. In summary, the patient presented exhibits an unusual coincidence of
different driver mutations among her leiomyomas.
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Background
Uterine leiomyomas (UL) are likely to constitute the
most frequent symptomatic human tumors at all. Des-
pite a significant morbidity they can cause, the associ-
ated health disparities as well as the enormous costs
related to the disease surprisingly little is known about the
roots of leiomyoma development. Statistical correlations
and theories have been advanced to explain these frequent
and clinically highly relevant neoplasms. Somatic alter-
ations of the tumor genome still can be expected to give
important novel insights thus representing a solid base for
a better understanding.
As to their molecular pathogenesis UL present as a
heterogeneous group of diseases due to different driver
mutations part of which can be detected by cytogenetic
investigations while other somatic mutations are re-
stricted to single base exchanges, small deletions and
small insertions [1, 2]. Of these, those affecting the genes
encoding mediator subcomplex 12 (MED12) and high
mobility group protein AT-hook 2 (HMGA2) apparently
characterize two independent types of UL [3–5]. In con-
trast to other genetic abnormalities non-randomly seen
in UL, both these genetic alterations have not been ob-
served to coexist within one tumor and even their coex-
istence in different UL tumors of one patient appears to
be a very rare finding [6]. Recently, evidence has been
presented that UL tumors with these mutations also dif-
fer in their clinical behavior with e.g. HMGA2-rear-
ranged UL presenting with a larger average size than
those with MED12 mutations [4, 6]. Also, they tend to
occur as solitary nodules [6] whereas often multiple
clonally independent leiomyomas with MED12 muta-
tions have been described. Furthermore, the literature
holds several examples of leiomyosarcomas and STUMP
(smooth muscle tumors of uncertain malignant poten-
tial) carrying MED12 mutations indistinguishable from
those found in “ordinary” UL [7–13]. These latter cases
suggest a rare but existing leiomyoma - STUMP - leio-
myosarcoma sequence likely depending on the occur-
rence of further genetic alterations in addition to the
driver mutation of MED12. In contrast, neither STUMP
nor uterine leiomyosarcomas with HMGA2 alterations
akin to those seen in UL have been reported so far.
However, considering the ongoing discussion of the risk
of tumor spread due to power morcellation, any attempts
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to gain further insights into the molecular pathogenesis of
malignant transformation within UL are of high interest.
As to alterations of the two genes MED12 and
HMGA2 there is ample evidence that we really deal with
two pathogenetically and clinically distinct tumor en-
tities. Here we describe the results of our genetic studies
on UL of a woman apparently carrying both types of
tumors along with those having other driver mutations.
The implications of our findings with respect to the
pathogenetic relevance of different driver mutations will
be discussed.
Case presentation
A 48 year old patient underwent laparotomic hysterec-
tomy because of symptomatic uterine leiomyomas. After
hysterectomy, gross examination revealed the presence
of four leiomyomas ranging in diameter between 3 cm
and 8 cm. Histologic examination of all four UL tumors
revealed typical benign smooth muscle tumors NOS
(“not otherwise specified”) without evidence for UL vari-
ants or STUMP lesions. Shortly after hysterectomy the
patient was diagnosed with an ER/PR-negative breast can-
cer that showed overexpression of HER2/neu, but one
year after hysterectomy no evidence for recurrence of
uterine tumors, as e.g. peritoneal spreading, was obtained.
Pieces of four UL tumors were obtained from the hys-
terectomy specimen. Molecular and cytogenetic analyses
of these four UL tumors were carried out. Cytogenetic
analyses failed to detect clonal karyotypic aberrations in
two of the UL tumors (UL 709/3 and 709/4. Fig. 1a-d,
Additional file 1: Table S1) and one of the UL tumors
carried a MED12 mutation (709/2. c.131G > A, Fig. 1e).
In contrast to the results obtained by G-banding, the
CNV arrays revealed more or less gross genomic alter-
ation in all four UL tumors (Fig. 2) that in neither of the
UL tumors could have escaped detection by G-banding.
E.g., in two UL tumors losses within the close surround-
ing of or within the HMGA2 locus point to rearrange-
ments of this gene (Fig. 3a, b). As other genomic
alterations frequently seen in UL, two of the UL tumors
were characterized by deletions of the long arm of
chromosome 7 with different sizes.
Fig. 1 Cytogenetic and molecular analysis of uterine leiomyomas. a-d representative G-banded karyotypes of four uterine leiomyomas. a tumor 709/1,
Karyotype: 45,XX,del(3)(q24q25.33),del(7)(q11.2),add(9)(q34),-15,der(17)t(15;17)(q?22;p?11.2)[3]/46,XX[3]. Of ten additional hypodiploid metaphases seven
showed structural abnormalities and losses and three only losses of chromosomes. In contrast to the structural abnormalities, none of the losses
observed were clonal. b tumor 709/2, karyotype: 43 ~ 46,XX,del(1)(p34),der(2),-11 +mar. c tumor 709/3, karyotype: 46,XX[22]. d tumor 709/4, karyotype:
46,XX[17]. e mutation of MED12 (c.131G > A) of tumor 709/2
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Of note, UL 709/3, presented with two deletions
located on either side of the HMGA2 locus. Of these, a
short 5′proximal deletion mapped outside the putative
transcription start of the gene removing a segment of
only approximately 280 kbp (Fig. 3a). A much larger de-
letion of roughly 42.79 Mb had removed part of the 3′
UTR of the gene. In terms of G-banding this latter dele-
tion resulted in the partial monosomy for the bands
12q14.3-q24.11. HMGA2 mRNA expression analysis car-
ried out in this case revealed a slightly elevated expres-
sion compared to other UL without clonal cytogenetic
abnormalities but was clearly lower than in cases with
cytogenetically apparent rearrangement of the 12q14-15
region (Fig. 4). As not uncommon in UL with HMGA2
rearrangements this tumor in addition had a deletion of
part of a terminal region of the long arm of chromosome
1 with a size of approximately 14.11 Mb affecting
chromosomal bands 1q42.2-q44 including the fumarate
hydratase gene (FH). Both the large deletion of 12q as
well as those of 1q should be detectable by G-banding
but neither clonal karyotypic abnormalities were seen in
this case nor was even a single metaphase seen
Fig. 2 Results of CNV-array-analyses. Whole genome views of four uterine leiomyomas investigated. The weihghted log2 ratio of the probes are
displayed as colored dots, the smooth signal (Gaussian smoothed calibrated copy number estimate) is displayed as blue line. a tumor 709/1. b
tumor 709/2. c tumor 709/3. d tumor 709/4
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presenting with these abnormalities. The second UL
(709/4) with a putative HMGA2 rearrangement presented
with deletions that both mapped proximal to the gene
locus again including one large and one smaller deletion.
The large deletion had a size of approximately 13.44 Mb
and mapped within chromosomal region 12q12-q13.3
whereas the small deletions had a size of only approxi-
mately 630 kbp and mapped in the direct vicinity of
HMGA2. From the array results it cannot even be ruled
out that by this deletion part of the exons 1 and 2 of the
gene had been removed (Fig. 3b). In addition, this UL car-
ried three deletions on the long arm of chromosome 7
that were interspersed with short non-deleted fragments
leading to a total loss of roughly 89,05 Mb from chromo-
somal region 7q11.22-q36.3. In this case as well, neither
evidence for the presence of chromosomal alterations in
general nor for those involving the deleted regions as
detected by the array analysis was obtained. Thus, as the
most likely explanation, in both UL tumors affected by
HMGA2 rearrangements the tumor cells did escape detec-
tion by G-banding due to their reduced ability or even
inability to proliferate in vitro.
Of the two UL tumors presenting no evidence for a
HMGA2 rearrangements as detected by G-banding or array
analysis (709/1, 709/2) one had a MED12 mutation but
both showed large deletions of the short arm of chromo-
some 3. Of note, the deleted segments in both UL tumors
caused a removal of the gene encoding MED12L (Fig. 3c).
In addition, both UL carried other large deletions that, in
these both UL tumors akin to the deletions of 3p, did not
escape detection by G-banding (Tab.1). However, of note in
case of 709/2 with the MED12 mutation the cytogenetic
preparation resulted in only two metaphases which could
be investigated. Both shared cytogenetic abnormalities that
thus can be considered being clonal (Fig. 1).
Conclusions
Among the few putative driver mutations observed in
UL those affecting MED12 and these leading to rear-
rangements of HMGA2 are particularly frequent and so
far never have been reported to coincide within one in-
dividual tumor. Also, patients harboring UL of both
types seem to be very rare. The present case deals with
one such coincidence. Being studied by G-banding as
Fig. 3 Rearrangements of chromosome 12 and deletions of the long arm of chromosome 3. a losses of parts of chromosome 12 in tumors 709/3
and 709/4. Black arrowheads indicate the region enlarged in (b). b. position of the HMGA2 gene with intron/exon structure as indicated in a. c.
Position of interstitial deletions of the long arm of chromosome 3 in tumors 709/1 and 709/2, respectively. The grey line and a black arrowhead
indicate the position of the MED12L gene
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well as by molecular analyses i.e. MED12 sequencing
and CNV arrays all four UL tumors revealed individual
patterns of genomic alterations indicating their independ-
ent clonal origin. Simultaneously, a rare coincidence of
several putative driver mutations displayed by the single
tumor was noted.
In two of them the profiles point to rearrangements of
HMGA2 that had escaped detection by G-banding. In
general, two explanations are possible for this lack of de-
tection. First, the underlying rearrangements may have
occurred at a submicroscopic level. This explanation
likely does not fit because the large deletions accom-
panying both alterations are in a range easily detectable
even when only applying a low resolution of chromo-
somal bands. Alternatively, the findings can be explained
by a reduced or even absent ability of the affected cells
to proliferate in vitro. Such a reduced ability recently has
been observed for cell cultures of MED12 mutated UL
[14]. Nevertheless, in that study cells of HMGA2-mu-
tated UL were able to proliferate for numerous in vitro
passages. At a first glance, this finding seems to contra-
dict the latter explanation for the absence of metaphases
with the said deletions. In the present study, however,
both UL tumors with presumed HMGA2 rearrange-
ments did also show other apparently independent ab-
normalities i.e. a large deletion of the long arm of
chromosome 1 in UL 709/3 and a large deletion of the
long arm of chromosome 7 in UL 709/4. Both abnormal-
ities have been described in UL before either in the pres-
ence or in the absence of structural rearrangements of
chromosome 12 [15–17]. Likewise, deletions of the long
arm of chromosome 7 can by accompanied by MED12
Fig. 4 Expression of HMGA2 mRNA in fibroid 709/3 as compared to ten other arbitrarily chosen fibroids without cytogenetically detectable
rearrangements of chromosomal region 12q14-15 (white columns) as well as to 19 fibroids that showed a microscopically visible rearrangement
of this chromosomal segment (grey columns), respectively
Table 1 Karyotypes and culture conditions of the tumors




Ten additional metaphases were hypodiploid. Of these, seven
showed structural abnormalities and losses and three only losses
of chromosomes. None of the losses observed were clonal.
709/2 43 ~ 46,XX,del(1)(p34)[[2],der(2)[2],-11[2],+mar[2][cp2] 35
709/3 46,XX[22] 35
709/4 46,XX[17]/44,XX,-19,-21[1] 20
Holzmann et al. Molecular Cytogenetics  (2015) 8:76 Page 5 of 7
mutations or occur independently [3]. In our recent study
on the in vitro proliferation of UL cells the vitro “long
term survivors” did not show one of these abnormalities
[14]. It seems reasonable to assume that, independent of
their coincidence with other driver mutations, both abnor-
malities reduce in vitro proliferation. In turn, the actual
frequency of HMGA2 rearrangements may be underesti-
mated when based solely on cytogenetics. In case of re-
duced ability to proliferate, whole genome sequencing [4]
as well as genomic array analysis seem to be more efficient
to detect these rearrangements if they are accompanied by
simultaneous losses of chromosomal material. Of note,
even when showing cytogenetic abnormalities of 12q14-15
microscopic analyses may not reflect the complexity of
underlying HMGA2 rearrangements sufficiently. Vice
versa, the mere number of genetic imbalances as such
does not allow diagnosing malignant growth [18].
Another interesting aspect in the UL tumors presented
herein relates to the deletion of the long arm of chromo-
some 3 found in two UL tumors including one without
detectable rearrangements of HMGA2 or MED12 muta-
tions. Deletions of the long arm of chromosome 3 re-
peatedly have been described before in UL. In their
study on 52 uterine leiomyomas with clonal chromo-
some abnormalities, Dal Cin P, Moerman P, Deprest J,
Brosens I, Van den Berghe H. identified eight tumors
with cytogenetic alterations that did not fit with any
well-delineated cytogenetic subgroup [19]. In three of
these cases the long arm of chromosome 3 was involved.
Accordingly, it was considered that these changes
characterize a new cytogenetic subgroup of uterine leio-
myomas. Given that these deletions all point to the same
target gene a loss-of-function for genes in that region as
e.g. HLTF, SIAH2, RAP2B, MME, GMPS, MLF1 und
RARRES1 should be considered. On the other hand in
both UL tumors presented herein MED12L mapped
within the region of overlap. The strong similarity be-
tween both genes and their proteins makes it reasonable
to consider an independent role of alterations of that
gene for the molecular pathogenesis in rare cases of UL.
In summary, the present case demonstrates the rare
occurrence of a marked genetic heterogeneity among
uterine leiomyomas with every single tumor displaying a
unique CNV pattern. Loss of heterozygosity affecting the
MED12L locus represents a candidate of a possible novel
driver mutation in UL. Given the low but albeit existing
probability of malignant transformation within UL the
results point to the number of UL tumors as a risk factor
associated with power morcellation of uterine tumors.
Methods
Tumor samples
From each of the UL tumors (lab code 709/1 - 709/4)
one part was fixed for histologic examination, another
part was snap frozen in liquid nitrogen, and a third part
was kept in Hank’s solution for subsequent cell cultures.
Histologic examination
The tumors were fixed in paraformaldehyde (4% in PBS)
and processed for paraffin embedding. Tissue sections
(1–2 μm thickness) were deparaffinized in xylene, rehy-
drated through a series of ethanol, and stained with
hematoxylin and eosin (H&E).
Cytogenetic studies
Chromosome analyses of cell cultures were performed
following routine techniques as described earlier [20].
DNA isolation
For CNV analysis as well as MED12 mutation analysis
DNA from the frozen tissue samples was isolated using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
on a QIACube (Qiagen) according to the manufacturer’s
instructions. The amount of double stranded DNA was
measured using the Qubit dsDNA HS Assay Kit and a
Qubit Fluorometer (Life Technologies, Carlsbad, CA).
PCR and sequencing
For PCR amplification 100 ng of genomic template
DNA were used. Primers to amplify the desired human
PCR fragment of the MED12 gene were those recently
described [15]. Subsequently, PCR-products were sepa-
rated by agarose gel-electrophoresis and the desired
DNA-fragments/-bands were extracted by a QIAquick
Gel Extraction Kit (Qiagen) using a QIACube (Qiagen)
according to manufacturer’s instructions. DNA-sequencing
of the purified PCR-products was performed using the
CEQ DTCS Quick Start Sequencing Kit and a Beckman
Coulter GenomeLab GeXP Genetic Analysis System (AB
SCIEX, Framingham, MA, USA).
Arrays
CNV (copy number variation) analysis was performed
using premade CytoScan HD Arrays (Affymetrix, Santa
Clara, CA) consisting of more than 2.4 million markers
for copy number and approximately 750,000 single nu-
cleotide polymorphisms (SNPs). Enriched gene coverage
for cancer and constitutional genes results in marker-
base ratio coverages of 1/384 for ISCA, 1/553 for cancer
genes, 1/486 for X-chromosomal genes and 1/659 for
12,000 OMIM genes. Labelling of 250 ng DNA and
hybridization were done following the manufacturer’s
instructions. After staining and washing using a Gene-
Chip Fluidics Station 450 (Affymetrix) the arrays were
scanned by an Affymetrix 3000 7G scanner. Arrays were
analyzed through the Affymetrix Chromosome Analysis
Suite (ChAS) software (ChAS analysis files for CytoScan®
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HD Array version NA33). Numbering of map positions
was based on hg19 (NCBI Build 37 reference sequence).
Quantification of HMGA2 mRNA
Expression of HMGA2 mRNA was analysed as described
earlier [21]. Briefly, RNA isolated from the samples had
been was digested by DNAse and then used for cDNA
synthesis. For quantification by real-time PCR (Applied
Biosystems 7300, Applied Biosystems, Darmstadt,
Germany), a commercially available gene expression assay
(Hs00171569, Applied Biosystems) was used. HMGA2
mRNA expression was quantified relatively to HPRT
mRNA, which was used as an endogenous control.
Consent
The study was approved by the local ethics committee.
Samples were obtained in accordance with the declar-
ation of Helsinki and informed written consent was ob-
tained from the patient prior to surgery.
Additional file
Additional file 1: Table S1. Results of array analysis. Overview of copy
number variations with 200 kb minimal size. (DOCX 29 kb)
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